FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutated Advanced Breast Cancer
The US FDA has granted accelerated approval to Etcamah (camizestrant) for adults with HR-positive, HER2-negative, locally advanced or metastatic breast cancer. It is approved in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) for patients in whom an ESR1 mutation is detected, using an FDA-authorised test, during treatment with an aromatase inhibitor plus a CDK4/6 inhibitor.
ESR1 mutations are acquired resistance mutations. Fewer than 5% of patients have one at diagnosis of metastatic disease, but nearly 40% do after progression on an aromatase inhibitor. The approval was based on progression-free survival measured from when the mutation was first found in the blood. The FDA has required confirmatory studies to show that switching treatment at that point gives a real clinical benefit.
Key points
- Drug: camizestrant (Etcamah), given with abemaciclib, palbociclib or ribociclib.
- For HR+/HER2- advanced breast cancer with an ESR1 mutation found during AI plus CDK4/6 inhibitor therapy.
- The FDA describes it as the first cancer therapy approval guided by detecting a resistance mutation before disease progression.
- Accelerated approval; confirmatory studies are required.
What it means for you
Oncologists and oncology pharmacists should note that this strategy depends on repeated ESR1 testing in the blood. Check with DRAP about whether camizestrant is registered or available in Pakistan.
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.